Login to Your Account



BMS to Take $1.8B Hit in 3Q

Heart, Kidney Failure Mark End of the Road for BMS HCV Drug

By Catherine Shaffer
Staff Writer

Monday, August 27, 2012

Bristol-Myers Squibb Co. shut down development of its hepatitis C virus (HCV) drug, BMS-986094, following a fatality and nine hospitalizations in a Phase II trial of the drug. The trial was suspended on Aug. 1, and the FDA placed the compound on clinical hold. BMS and the FDA are working together to follow up on the incidents, which involve heart and lung toxicity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription